Clinical trialNCT07109414Active, not recruitingPhase 2/PHASE3Interventional

Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)

SponsorNovita Pharmaceuticals, Inc.Enrollment380Platinum-resistant Ovarian Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of the study is to identify the optimal dose level of NP-G2-044 in combination with standard of care (SOC) pegylated liposomal doxorubicin (PLD), and to compare the efficacy and safety of NP-G2-044+PLD vs. PLD alone in participants with platinum-resistant ovarian cancer (PROC).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Jillian Zhang, PhD
Novita Pharmaceuticals, Inc.
Study Director
clinicaltrials.gov ↗
Lisa Barroilhet, MD
University of Wisconsin, Madison
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Honorhealth Cancer Care
Phoenix, Arizona, United States
Trials365
Shreveport, Louisiana, United States
Optimum Clinical Research Group, Llc
Albuquerque, New Mexico, United States
University of Pennsylvania Health System, Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, United States
Utah Cancer Specialists
Salt Lake City, Utah, United States
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

NP-G2-0441-Dodecylpyridoxal chloride

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 29 Dec 2025
Primary completion: 25 Oct 2028
Completion: 24 Oct 2029
Last update posted: 9 Mar 2026
Registered enrollment: 380
Registry id: NCT07109414

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.